Difference between revisions of "Team:Duke/Human Practices"

Revision as of 02:44, 19 October 2016

Our group was able to focus on two different areas of Human Practices. One area of focus is on the patentability of an engineered bacteria while the other area of focus was on the societal impacts if the engineered bacteria were to be used in society. Our group was also part of an educational outreach program.

@@ Line 9: / Line 9: @@
 <div class="column full_size">
-<h2> Overview of the Projects</h2>
+<h2> Our Projects</h2>
 <br>
+<h3> An Overview and Analysis of the Societal Impacts of Taxol Biosynthesis in the United States</h3>
 <h3> Patenting a New Form of Taxol Fermentation </h3>
-<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxol, also known as pacilitaxel, is a widely used chemotherapy drug typically
+<h3> Educational Outreach </h3>
-extracted from the Yew tree. Mere extraction, however, does not yield sustainable returns
-because too-frequent extraction involves destroying the Yew tree source. Demand for Taxol
-has outstripped supply, and scientists have turned to developing Taxol in plant cells followed
-by industrial fermentation. The Duke University International Genetically Engineered
-Machine Project looks to go a step further, by generating Taxol in bacteria cell cultures
-instead of plant cell cultures. In order to use this invention to boost the market supply of
-Taxol, the IGEM team will eventually need a corporate or non-profit partner, and this partner
-will only be incentivized to participate if the IGEM team can offer exclusive licensing. Thus, the
-success of IGEM’s new genetically engineered bacteria largely hinges on its patentability with
-the United States Patent and Trademark Office. This report walks through the relevant patent
-requirements, analyzes the case law, and comes to the conclusion that IGEM’s new genetically
-engineered bacteria meets the conditions for successful patentability.</Pre></p>
 <!--